Atossa Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Atossa Therapeutics, Inc.
Private Company Edition: Playground’s third fund has $410m for tech, including biotech, Pivotal Life Sciences closed its second fund with $389m and Chugai will invest $200m through its new fund. Also, Tome launched with $213m, Sudo raised a $116m series B and Odyssey closed a $101m in series C.
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
Coronavirus Notebook: WHO Accelerator Project Languishes, Novel Treatments Are Explored, Gilead Submits US Remdesivir Filing
Gilead files for US approval of remdesivir and boosts investment in manufacturing capacity, more funding is needed for the global ACT Accelerator initiative, and the US and China are rated among the worst responders to the COVID-19 pandemic.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
- Other Names / Subsidiaries
- Atossa Genetics, Inc.
- National Reference Laboratory for Breast Health (NRLBH)
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.